The rapid progression of IDH1/2 mutant enzyme inhibitors through clinical trials
Stéphane de Botton
Germline predispositions in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
Jane E. Churpek
Finding the right targets for CAR T-cell therapy in AML
The Hokusai VTE-Cancer Study: objectives and design
Are there promising treatment options for multiple myeloma on the horizon?